Search
GT Biopharma Inc
GTBPAdd to Watchlist
0.290USD
-0.018-5.69%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.76MMarket Cap
LossP/E TTM
More Details of GT Biopharma Inc Company
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
GT Biopharma Inc Info
Ticker SymbolGTBP
Company nameGT Biopharma Inc
IPO dateOct 22, 2013
CEOBreen (Michael)
Number of employees1
Security typeOrdinary Share
Fiscal year-endOct 22
Address505 Montgomery Street
CitySAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94111
Phone18003049888
Websitehttps://www.gtbiopharma.com/
Ticker SymbolGTBP
IPO dateOct 22, 2013
CEOBreen (Michael)
Company Executives of GT Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Alan Louis Urban
Mr. Alan Louis Urban
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
75.00K
+33.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
62.50K
--
Mr. Michael Breen
Mr. Michael Breen
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Ms. Hilary Kramer
Ms. Hilary Kramer
Independent Director
Independent Director
--
--
Mr. David Mun-Gavin
Mr. David Mun-Gavin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Corey Davis
Mr. Corey Davis
IR Contact Officer
IR Contact Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Alan Louis Urban
Mr. Alan Louis Urban
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
75.00K
+33.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
62.50K
--
Mr. Michael Breen
Mr. Michael Breen
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Ms. Hilary Kramer
Ms. Hilary Kramer
Independent Director
Independent Director
--
--
Mr. David Mun-Gavin
Mr. David Mun-Gavin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Corey Davis
Mr. Corey Davis
IR Contact Officer
IR Contact Officer
--
--
FAQs
Who are the top five shareholders of GT Biopharma Inc?
The top five shareholders of GT Biopharma Inc are: Mr. Alan Louis Urban
How many institutions hold shares of GT Biopharma Inc (GTBP)?
As of 2026Q1, 67 institutions hold shares of GT Biopharma Inc, with a combined market value of approximately 2.14M, accounting for 6.79% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 183043.00.